948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors
    Journal Article

    Kim, T. W.; Burris, H. A. 3rd; de Miguel Luken, M. J.; Pishvaian, M. J.; Bang, Y. J.; Gordon, M.; Awada, A.; Camidge, D. R.; Hodi, F. S.; McArthur, G. A.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial
    Journal Article

    Padrón, L. J.; Maurer, D. M.; O’Hara, M. H.; O’Reilly, E. M.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial
    Journal Article

    Brümmendorf, T. H.; Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; Clark, R. E.; le Coutre, P.; Garcia-Gutierrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • Metformin for treatment of cytopenias in children and young adults with Fanconi anemia
    Journal Article

    Pollard, J. A.; Furutani, E.; Liu, S.; Esrick, E.; Cohen, L. E.; Bledsoe, J.; Liu, C. W.; Lu, K.; de Haro, M. J. R.; Surrallés, J.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Safety of tepotinib in patients with MET exon 14 skipping NSCLC and recommendations for management
    Journal Article

    Veillon, R.; Sakai, H.; Le, X.; Felip, E.; Cortot, A. B.; Smit, E. F.; Park, K.; Griesinger, F.; Britschgi, C.; Wu, Y. L.; more...
    Clinical Lung Cancer (2022)

    Fulltext@MSK | Save
  • EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study
    Journal Article

    Zauderer, M. G.; Szlosarek, P. W.; Le Moulec, S.; Popat, S.; Taylor, P.; Planchard, D.; Scherpereel, A.; Koczywas, M.; Forster, M.; Cameron, R. B.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors
    Journal Article

    Choudhury, A. D.; Higano, C. S.; de Bono, J. S.; Cook, N.; Rathkopf, D. E.; Wisinski, K. B.; Martin-Liberal, J.; Linch, M.; Heath, E. I.; Baird, R. D.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Familial colloid cysts: Not a chance occurrence
    Journal Article

    Giantini-Larsen, A. M.; Garton, A. L. A.; Villamater, F. N.; Kuzan-Fischer, C. M.; Savage, N. J.; Cunniff, C. M.; Ross, M. E.; Christos, P. J.; Stieg, P. E.; Souweidane, M. M.
    Journal of Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study
    Journal Article

    Diaz, L. A. Jr; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Ibrutinib associated with rituximab-platinum salt-based immunochemotherapy in B-cell lymphomas: Results of a phase 1b-II study of the LYSA group
    Journal Article

    Bonnet, C.; Dupuis, J.; Tilly, H.; Lamy, T.; Fruchart, C.; le Gouill, S.; Thieblemont, C.; Morschhauser, F.; Casasnovas, O.; Bouabdallah, K.; more...
    Cancers (2022)

    Fulltext@MSK | Save